Belgium Encircled by heavyweight life sciences powerhouses of the likes of Germany, France and Switzerland, plucky Belgium nonetheless continues to astonish and project considerable influence when it comes to its abilities to develop, manufacture and sell medicines. Despite representing only a mid-size marketplace from an in-country commercial perspective, the comparatively…
Belgium Celltrion Healthcare Belgium’s Nicolas Van Gelder introduces the concept of ‘biobetters’ and how they differ from standard biosimilars and originator biologics, the reception and uptake of these products so far in the Belgian market, and what he sees as Celltrion’s role as driving savings and positive change in the country’s…
South Korea South Korea has carved a place for itself as a dominant player in the global pharma and med-tech manufacturing industry with national companies Samsung Biologics and Celltrion leading the way. In 2019, the South Korean government announced a USD 1.7 billion five-year plan to fund biotech-related projects with the intention…
Korea Two decades ago, South Korean company Celltrion embarked on a quest to find the necessary resources to produce biopharmaceuticals. It took five years for their manufacturing plant to receive GMP certification from the US FDA in 2007 and another one to launch an initial public offering; an ascent that, while…
Turkey Best known as the company that launched the world’s first “antibody biosimilar,” Celltrion is looking to continue its growth as a global biopharmaceutical company. Its general manager for Turkey, SeokHoon Kang and commercial director, Mahmut Uyar, outline the Korean company’s strong performance in 2020, how they are leveraging their commercial…
Switzerland Laurent Massuyeau introduces Swiss biosimilar commercialisation specialist iQone healthcare, why it made sense to base the company in Switzerland, its partnership deal with Korean biosimilar giant Celltrion, and where iQone’s future lies. For me, Switzerland is one of the best places in Europe to start a business Having previously…
Korea Korean biosimilar firm Celltrion’s USD 266 million acquisition of Japanese outfit Takeda assets in the Asia-Pacific region marks a significant moment in Celltrion’s international expansion as well as yet another big-money deal for Takeda. Since Takeda’s earthshattering announcement of its intended USD 62 billion acquisition of Shire – the…
See our Cookie Privacy Policy Here